Lantheus (LNTH) Competitors $53.55 +1.71 (+3.30%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$53.58 +0.03 (+0.06%) As of 10/8/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LNTH vs. ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, and RVMDShould you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), Qiagen (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Lantheus vs. Its Competitors Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna Qiagen Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Lantheus (NASDAQ:LNTH) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Do institutionals & insiders have more ownership in LNTH or ASND? 99.1% of Lantheus shares are owned by institutional investors. 1.5% of Lantheus shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, LNTH or ASND? Lantheus has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Does the media prefer LNTH or ASND? In the previous week, Lantheus had 22 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 28 mentions for Lantheus and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.36 beat Lantheus' score of 0.04 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend LNTH or ASND? Lantheus presently has a consensus target price of $74.50, indicating a potential upside of 39.12%. Ascendis Pharma A/S has a consensus target price of $244.36, indicating a potential upside of 16.29%. Given Lantheus' higher probable upside, analysts plainly believe Lantheus is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has stronger valuation & earnings, LNTH or ASND? Lantheus has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.53B2.37$312.44M$3.7614.24Ascendis Pharma A/S$393.54M32.94-$409.12M-$5.16-40.72 Is LNTH or ASND more profitable? Lantheus has a net margin of 17.82% compared to Ascendis Pharma A/S's net margin of -54.94%. Lantheus' return on equity of 34.06% beat Ascendis Pharma A/S's return on equity.Company Net Margins Return on Equity Return on Assets Lantheus17.82% 34.06% 19.10% Ascendis Pharma A/S -54.94%N/A -24.31% SummaryLantheus beats Ascendis Pharma A/S on 10 of the 16 factors compared between the two stocks. Get Lantheus News Delivered to You Automatically Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNTH vs. The Competition Export to ExcelMetricLantheusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.52B$10.57B$6.10B$10.55BDividend YieldN/A1.87%5.69%4.75%P/E Ratio14.2421.8785.4727.60Price / Sales2.3732.51601.78232.87Price / Cash7.3125.4637.9261.55Price / Book3.423.4513.136.76Net Income$312.44M$208.83M$3.30B$275.88M7 Day Performance1.63%1.63%4.29%2.81%1 Month Performance-2.76%2.06%9.45%9.24%1 Year Performance-50.99%-5.12%86.64%35.42% Lantheus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNTHLantheus4.64 of 5 stars$53.55+3.3%$74.50+39.1%-50.5%$3.52B$1.53B14.24700Trending NewsAnalyst ForecastASNDAscendis Pharma A/S3.0175 of 5 stars$191.60-0.2%$244.36+27.5%+59.1%$11.81B$393.54M-37.131,017News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories3.2752 of 5 stars$13.96-1.9%$16.95+21.5%-11.1%$11.65B$3.81B21.1427,811News CoveragePositive NewsAnalyst ForecastVTRSViatris1.6652 of 5 stars$9.62+1.1%$10.40+8.1%-11.9%$11.22B$14.74B-3.3232,000Analyst ForecastROIVRoivant Sciences3.5482 of 5 stars$15.10-0.5%$19.94+32.0%+42.1%$10.31B$29.05M-21.57860Analyst ForecastInsider TradeBBIOBridgeBio Pharma4.1972 of 5 stars$51.96+3.8%$63.94+23.1%+123.6%$9.93B$221.90M-12.70400Analyst ForecastMRNAModerna4.3127 of 5 stars$25.33+3.4%$41.81+65.1%-52.2%$9.86B$3.24B-3.365,800Analyst ForecastQGENQiagen4.3007 of 5 stars$43.880.0%$49.69+13.2%+12.8%$9.75B$1.98B25.935,765Analyst ForecastELANElanco Animal Health2.684 of 5 stars$19.63+0.1%$18.33-6.6%+40.6%$9.75B$4.44B22.829,000Trending NewsAnalyst UpgradeVRNAVerona Pharma PLC American Depositary Share2.1248 of 5 stars$106.61-0.1%$109.00+2.2%N/A$9.19B$42.28M-107.6930News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.2719 of 5 stars$46.07+4.9%$74.64+62.0%-3.9%$8.61B$11.58M-10.24250Analyst Forecast Related Companies and Tools Related Companies ASND Competitors RDY Competitors VTRS Competitors ROIV Competitors BBIO Competitors MRNA Competitors QGEN Competitors ELAN Competitors VRNA Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNTH) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
